Compugen Ltd. Stock Deutsche Boerse AG
Stocks
CW9
IL0010852080
Biotechnology & Medical Research
| Market Cap | 221M 195M 181M 166M 312M 21.43B 317M 2.16B 843M 10.45B 831M 813M 36.27B | P/E 2026 * |
-8.07x | P/E 2027 * | -8.18x |
|---|---|---|---|---|---|
| Enterprise Value | 221M 195M 181M 166M 312M 21.43B 317M 2.16B 843M 10.45B 831M 813M 36.27B | EV / Sales 2026 * |
23.5x | EV / Sales 2027 * | 13.8x |
| Free-Float |
97.92% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Compugen Ltd.
| 1 day | -2.88% |
| Manager | Title | Age | Since |
|---|---|---|---|
Eran Ophir
CEO | Chief Executive Officer | - | 2025-09-22 |
David Silberman
DFI | Director of Finance/CFO | 42 | 2024-08-14 |
Pierre Ferre
COO | Chief Operating Officer | 49 | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Anat Cohen-Dayag
CHM | Chairman | 59 | 2025-09-22 |
Gilead Halevy
BRD | Director/Board Member | 59 | 2018-06-10 |
Sanford Zweifach
BRD | Director/Board Member | 70 | 2018-06-10 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.88% | -9.82% | - | - | 229M | |
| +1.08% | -5.74% | -4.98% | +10.45% | 46.06B | |
| +3.13% | +5.34% | +402.93% | +605.08% | 38.91B | |
| +2.14% | +2.95% | +10.83% | +65.45% | 35.57B | |
| +4.43% | -1.51% | +6.73% | -9.17% | 33.13B | |
| +1.23% | -2.05% | +0.56% | +30.76% | 26.42B | |
| +0.29% | -2.75% | - | - | 16.61B | |
| +14.71% | +12.62% | +38.50% | +146.99% | 15.08B | |
| -6.32% | -4.86% | +4.36% | +8.22% | 14.08B | |
| +1.82% | +0.19% | +1.45% | -30.74% | 12.81B | |
| Average | +1.82% | -0.43% | +57.55% | +103.38% | 26.52B | |
| Weighted average by Cap. | +2.22% | -1.28% | +75.35% | +129.70% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 9.41M 8.28M 7.69M 7.07M 13.27M 912M 13.5M 91.98M 35.88M 445M 35.34M 34.58M 1.54B | 16.05M 14.11M 13.11M 12.06M 22.62M 1.55B 23.02M 157M 61.16M 758M 60.25M 58.94M 2.63B |
| Net income | -27.6M -24.27M -22.55M -20.74M -38.89M -2.67B -39.59M -270M -105M -1.3B -104M -101M -4.52B | -28.01M -24.64M -22.89M -21.05M -39.48M -2.71B -40.18M -274M -107M -1.32B -105M -103M -4.59B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
